Ryan Cohlhepp - 22 Jan 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role: President and COO, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact
Issuer symbol: BCAX
Transactions as of: 22 Jan 2026
Net transactions value: -$69,296
Form type: 4
Filing time: 26 Jan 2026, 16:34:51 UTC
Previous filing: 20 Jan 2026
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cohlhepp Ryan	President and COO, Director	BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON	/s/ Lara Meisner, Attorney-in-Fact	26 Jan 2026	0002034665

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCAX	Common Stock	Sale	$69,296	-3,828	-1.8%	$18.10	210,164	22 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.